Dyax appoints Burt Adelman CMO
This article was originally published in Scrip
Executive Summary
Biopharmaceutical company Dyax has appointed Dr Burt Adelman chief medical officer. Dr Adelman will lead the development and regulatory strategy for the company’s non-histamine-mediated angioedema franchise. He has experience in drug development and commercialisation, having served at Biogen Idec from 1991-2007 in roles of increasing responsibility, working on products including Avonex (interferon beta-1a) and Tysabri (natalizumab). He currently serves as a lecturer in medicine at the Harvard Medical School.
You may also be interested in...
Almirall launches Constella in six European markets
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira raises $35m in series B
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis ups public offering to $240m
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.